LONN: Recovery In Life Science Tools Demand Will Drive Future Upside

Narrative Update: Lonza Group

Analysts have trimmed their blended price target for Lonza Group by about CHF 13 to reflect lower fair value estimates and a higher discount rate, even as they point to early signs of recovery in life science tools demand and resilient profitability expectations.

Analyst Commentary

Recent research updates show that price targets for Lonza Group have been revised lower, even as some analysts highlight early recovery signs in key end markets. The focus remains on how the company executes against demand trends in life science tools and how that filters through to valuation.

Bullish Takeaways

Bullish analysts still frame Lonza as a Buy. This indicates they see the current share price as not fully reflecting their longer term expectations for the business despite lower targets.
Mentions of "green shoots of recovery" in areas like bioprocessing and quality assurance suggest some analysts see potential for improving growth in parts of Lonza's addressable markets.
Comments about resilient profitability expectations point to confidence that Lonza can manage costs and protect margins, which supports the earnings side of valuation models.
The view that the life science tools sector is priced for disappointment implies some analysts see room for upside if execution is solid and demand trends stabilise or improve.

Bearish Takeaways

All referenced research items involve lower price targets. This signals reduced fair value estimates and a more conservative stance on expected returns.
Analysts highlight that broader market expectations on life science tools remain bearish, which can cap valuation multiples for Lonza if sentiment stays weak.
A higher discount rate in valuation work raises the hurdle for future cash flows, reflecting greater perceived risk around the sector and company execution.
Preference by some analysts for other healthcare stocks, such as those focused on managed care or therapeutics, suggests Lonza may face tougher competition for investor capital in the sector.

What’s in the News

Lonza Group shareholders approved a dividend of CHF 5.00 per share at the annual general meeting on 8 May 2026, with 50% paid from capital contribution reserves and exempt from Swiss withholding tax. Source: Company AGM details.
Lonza is collaborating with Simulations Plus and the U.S. Food and Drug Administration on a funded research project to build a mechanistic, predictive framework for amorphous solid dispersion drug products, aiming to support model informed drug development and potentially reduce reliance on some clinical bioequivalence studies. Source: Simulations Plus announcement.
Management stated that proceeds from the planned sale of 60% of Capsugel Health Ingredients (CHI) to Lone Star, with an enterprise value at closing of CHF 2.3b and expected total proceeds around CHF 3b at full exit, are earmarked for bolt on M&A, organic growth and a CHF 500m share buyback, with a focus on expanding the contract development and manufacturing (CDMO) business. Source: Lonza Investor Conference Call.
Lonza reiterated plans to invest CHF 7,000m in organic growth between now and 2030, with additional capacity for bolt on acquisitions that add technologies, capacity and portfolio breadth, particularly in the U.S. Source: Lonza Investor Conference Call.
Lonza and Genetix Biotherapeutics extended their long term commercial manufacturing agreement for ZYNTEGLO, with Lonza set to expand capacity at its Houston cell and gene therapy facility and with provisions in place to scale further for future Genetix therapies. Source: Company client announcement.

Valuation Changes

Fair Value: Trimmed slightly from CHF 676.18 to CHF 663.52, reflecting a modest reduction in the central valuation estimate.
Discount Rate: Raised from 4.43% to 4.85%, implying a higher required return on Lonza Group's future cash flows.
Revenue Growth: Adjusted down a touch from 11.39% to 11.08%, signalling slightly more conservative assumptions for top line expansion in CHF terms.
Net Profit Margin: Marked up from 16.79% to 18.86%, indicating firmer expectations for profitability on future CHF earnings.
Future P/E: Eased from 31.82x to 31.26x, suggesting a modestly lower valuation multiple applied to projected earnings.

5 views

Key Takeaways

Sustained demand and investment in advanced manufacturing are driving stable, higher-margin growth and improved operational efficiency.
Divesting non-core segments and expanding globally enhance strategic focus, revenue resilience, and long-term capital allocation efficiency.
Heavy reliance on unstable business segments, high expansion risks, adverse currency trends, rising competition, and divestment pressures threaten profitability, growth, and financial flexibility.

Catalysts

About Lonza Group

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.What are the underlying business or industry changes driving this perspective?

Robust and sustained demand for Lonza's biologics and advanced therapy manufacturing capacity, driven by the global increase in chronic and complex diseases (notably oncology, autoimmune disorders, and new modalities like cell and gene therapies), is fueling long-term revenue growth with strong order visibility (as seen in high utilization rates and multi-year contracts), supporting top-line expansion and earnings stability.
Lonza's strategic and diversified investments in cutting-edge manufacturing facilities (notably in mammalian, bioconjugate, cell & gene, and highly potent APIs) and automation upgrades (including the ongoing Vacaville and Visp expansions) are set to capture growing customer demand for next-generation therapies and support operating leverage, pointing to higher-margin growth and improved group EBITDA margins.
Global pharma's ongoing shift toward outsourcing more complex manufacturing to specialized CDMOs, in tandem with increased biopharma R&D budgets, is sustaining high contract-wins, repeat business, and a diverse customer mix for Lonza, which underpins recurring revenue streams and reduces volatility in cash flow and earnings.
Geographical expansion (notably in the U.S., APAC, and Europe) and Lonza's strong networked global footprint offer increased resilience-minimizing risk from localized supply chain disruptions or tariffs-while helping to drive continued customer acquisition and revenue growth from multiple major markets, supporting long-term earnings.
The planned divestment of Capsules and Health Ingredients (CHI), a lower-growth, albeit cash-generative, segment, will free up capital for higher-return investments in core CDMO operations and potentially lift return on invested capital and free cash flow over the medium term, positively impacting future margins and capital allocation efficiency.

Lonza Group Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Lonza Group's revenue will grow by 11.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.9% today to 18.9% in 3 years time.
Analysts expect earnings to reach CHF 1.7 billion (and earnings per share of CHF 24.22) by about June 2029, up from CHF 909.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CHF2.0 billion in earnings, and the most bearish expecting CHF1.4 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 31.3x on those 2029 earnings, down from 37.3x today. This future PE is lower than the current PE for the GB Life Sciences industry at 35.9x.
Analysts expect the number of shares outstanding to decline by 0.32% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 4.85%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The Specialized Modalities business faces notable volatility due to reliance on a small pipeline of commercial Cell & Gene Therapy (CGT) products, leading to uneven asset utilization and sensitivity to clinical setbacks; this creates significant risk to both revenue stability and margins in that segment.
Expansion and ramp-up of major facilities (such as Vacaville and Visp) involve high CapEx intensity and operational execution risk; delays, underutilization, or cost overruns during this expansion period could lead to higher depreciation charges and reduced return on invested capital, negatively impacting future earnings and free cash flow.
Currency fluctuations, especially a strong Swiss franc against the US dollar, have created noticeable headwinds (−2.5% to −3.5% expected impact on sales and EBITDA for 2025), potentially reducing reported revenue and profit margins if the trend persists or intensifies.
Increasing competition and customer negotiations in the US CDMO market could pressure pricing and limit Lonza's ability to maintain margin expansion, particularly as new customer contracts are required to offset expiring legacy contracts (e.g., Roche at Vacaville); difficulties in signing sufficient large contracts may impair revenue growth and backlog.
The eventual divestment of Capsules and Health Ingredients (CHI), which is more cash-generative than the core CDMO business, may reduce the group's near-term free cash flow, while the CDMO business is still transitioning to a less CapEx-intensive, more cash-generative profile-posing a temporary risk to group-wide liquidity and financial flexibility.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF663.52 for Lonza Group based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF815.0, and the most bearish reporting a price target of just CHF550.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF9.0 billion, earnings will come to CHF1.7 billion, and it would be trading on a PE ratio of 31.3x, assuming you use a discount rate of 4.9%.
Given the current share price of CHF485.6, the analyst price target of CHF663.52 is 26.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Lonza Group?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Vacaville And Visp Facilities Will Secure Future Biologics Demand